ANTI-LAG-3 ANTIBODIES AND USES THEREOF

Title:

ANTI-LAG-3 ANTIBODIES AND USES THEREOF

Document Type and Number:

WIPO Patent Application WO/2018/153340

Kind Code:

A1

Abstract:

Provided are antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.

More Like This:

WO/2012/093754	COMPOSITION COMPRISING EXTRACELLULAR VESICLES DERIVED FROM INSIDE A MAMMALIAN BODY AND A USE THEREFOR
WO/2001/079511	HEMOLYSIN FUSION PROTEINS, THEIR PRODUCTION AND USE
WO/2022/035197	STABLE PHARMACEUTICAL FORMULATION

Inventors:

FANG LEI (CN)
WANG ZHENGYI (CN)
GUO BINGSHI (CN)
ZANG JINGWU (CN)
JIANG WENQING (CN)
WANG YONGQIANG (CN)

Application Number:

PCT/CN2018/076940

Publication Date:

August 30, 2018

Filing Date:

February 22, 2018

Export Citation:

Click for automatic bibliography generation Help

Assignee:

I MAB (KY)

International Classes:

A61K39/00; A61P35/00; C07K16/28; C12N15/13

Domestic Patent References:

WO2016028672A1

2016-02-25

Foreign References:

CN106103484A	2016-11-09
CN102176921A	2011-09-07
CN104411723A	2015-03-11
US20170022273A1	2017-01-26

Other References:

KOUO, T. ET AL.: "Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD 8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells", CANCER IMMUNOLOGY RESEARCH, vol. 3, no. 4, 17 February 2015 (2015-02-17), pages 412 - 423, XP002755464
HE, Y.Y. ET AL.: "Lymphocyte-activation gene -3, an important immune checkpoint in cancer", CANCER SCIENCE, vol. 107, 30 September 2016 (2016-09-30), pages 1193 - 1197, XP055540244
See also references of EP 3389702A4

Attorney, Agent or Firm:

SHANGHAI BESHINING LAW OFFICE (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: PERSONAL HANGING TYPE DOUBLE-RAIL AND DOUBLE-POWER AUTOMATIC CONTROL LIGHT RAIL TRAFFIC SYSTEM

Next Patent: SAMPLE ADDING SYSTEM FOR AUTOMATICALLY ADDING SPUTUM DIGESTION LIQUID